GW Pharmaceuticals PLC (GWPH) Stock Rating Lowered by ValuEngine
GW Pharmaceuticals PLC (NASDAQ:GWPH) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Monday.
A number of other analysts have also commented on the company. Maxim Group set a $135.00 target price on GW Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Thursday, June 8th. Zacks Investment Research raised GW Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $119.00 price target on the stock in a research note on Monday, July 17th. Cantor Fitzgerald set a $208.00 price target on GW Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Tuesday, August 8th. BidaskClub upgraded GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Finally, Leerink Swann reduced their price objective on GW Pharmaceuticals PLC from $160.00 to $153.00 and set an “outperform” rating for the company in a research note on Monday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. GW Pharmaceuticals PLC has an average rating of “Buy” and a consensus price target of $149.83.
GW Pharmaceuticals PLC (NASDAQ:GWPH) traded down 2.94% on Monday, hitting $98.51. The company had a trading volume of 1,297,826 shares. GW Pharmaceuticals PLC has a one year low of $92.65 and a one year high of $137.88. The stock’s 50-day moving average price is $105.31 and its 200 day moving average price is $108.39. The company’s market capitalization is $2.49 billion.
GW Pharmaceuticals PLC (NASDAQ:GWPH) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, missing the consensus estimate of ($1.73) by ($0.34). The company had revenue of $3.14 million for the quarter, compared to analyst estimates of $2.10 million. GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 28.80%. During the same quarter in the prior year, the company posted ($0.05) EPS. On average, analysts expect that GW Pharmaceuticals PLC will post ($5.94) EPS for the current fiscal year.
Institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC bought a new position in shares of GW Pharmaceuticals PLC in the second quarter valued at approximately $70,128,000. Redmile Group LLC boosted its position in shares of GW Pharmaceuticals PLC by 33.8% during the second quarter. Redmile Group LLC now owns 444,936 shares of the biopharmaceutical company’s stock valued at $44,605,000 after buying an additional 112,392 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of GW Pharmaceuticals PLC during the first quarter valued at approximately $10,909,000. Nomura Holdings Inc. purchased a new position in shares of GW Pharmaceuticals PLC during the first quarter valued at approximately $9,389,000. Finally, Employees Retirement System of Texas purchased a new position in shares of GW Pharmaceuticals PLC during the second quarter valued at approximately $5,313,000. 75.06% of the stock is owned by hedge funds and other institutional investors.
GW Pharmaceuticals PLC Company Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Stock Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.